Drugs / VH3810109
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07053384 | Jul 2025 → Jan 2027 expected | HIV infectious disease | ViiV Healthcare | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05291520 | Feb 2022 → Apr 2023 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05996471 | Aug 2023 → May 2026 overdue | HIV infectious disease | ViiV Healthcare | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VH3810109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05996471 ↗ |
| Known as | GSK3810109 | “Safety and pharmacokinetics of a single dose of VH3810109 (also known as GSK3810109), administered either subcutaneously (SC) with rHuPH20 or intravenously (IV)” NCT05291520 ↗1“single dose of VH3810109 (also known as GSK3810109), administered either subcutaneously” PMID 40698814 ↗ Jul 2025 |
| Known as | N6LS | “The CD4-binding site antibody VH3810109 (N6LS) demonstrated broad and potent neutralization activity in vitro and robust antiviral activity in people with HIV-1.” PMID 40698814 ↗ Jul 2025 |
| Route | Subcutaneous | “Participants in this group received a single subcutaneous (SC) dose of VH3810109 20 mg/kg co-administered with rHuPH20 at Day 1 and were followed up to 24 weeks.” NCT05291520 ↗ |